BDR Pharma signs agreement with DRDO to produce COVID-19 drug 2-DG

Date: 2021-07-27   Author: Pankaj Singh  Category: #news

BDR Pharma signs agreement with DRDO to produce COVID-19 drug 2-DG

BDR Pharma has reportedly signed a licensing agreement with the DRDO (Defence Research and Development Organisation) to produce, distribute, and promote COVID-19 drug 2-DG (2-Deoxy-D-Glucose) in India.

The Mumbai-based company has inked an agreement with DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) and the Defence Research and Development Establishment (DRDE) for producing, distributing, and promoting the COVID-19 drug in the country.

Last month, the DCGI (Drugs Controller General of India) sanctioned the oral medication as an immunity booster for emergency usage in COVID-19 patients with mild to severe symptoms.

Recently, DRDO signed agreements with four key generic medicine producers from India for developing 2-DG drugs. The DRDE has manufactured the 2-DG and its clinical trials were performed by the DRDO lab INMAS in partnership with Dr. Reddy's Laboratories.

BDR Pharma has already applied for restricted emergency use authorization to the Drug Controller General of India (DCGI), in order to use the drug for treating COVID-19 patients in India.

Dharmesh Shah, the CMD of BDR Pharmaceuticals, supposedly commented that the company is delighted to sign a license pact with the DRDO and add 2-DG to its COVID-19 product portfolio. The goal of this arrangement is to make this drug available to as many eligible Indian COVID-19 patients as possible.

He added that the company is aiming at increasing the availability of successful treatment and will coordinate manufacturing accordingly. This will ensure there is no dearth of drugs for people fighting this devastating disease.

Shah further said that this partnership will cater to more unmet medical needs, by increasing the scope of identification and development of therapy options for COVID-19.

2-DG will be offered in a sachet in powdered form and can be consumed orally by dissolving it in water, and will be made available at an economical price point.

Source credits:

https://www.moneycontrol.com/news/india/bdr-pharma-inks-license-agreement-with-drdo-to-produce-covid-19-drug-2-dg-7224931.html



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

RELX enters KSA distribution partnership with SAF Trading Agencies

Author: Pankaj Singh

RELX International has reportedly partnered with SAF Trading Agencies for the exclusive distribution of RELX e-liquid nicotine products and e-cigarette devices across the Kingdom of Saudi Arabia.

Rigid Mine Dumper market share to record robust growth through 2026

Author: Ashwin Naphade

Market Study Report has added a new report on Rigid Mine Dumper market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dyna...


New Report On Data Center Monitoring Solution Market Evolving Technology and Growth Outlook 2021 to 2026

Author: Ashwin Naphade

Data Center Monitoring Solution market to expand significantly during 2021-2026. The report includes information pertaining to the major market trends, product type, application reach, competitive scope, CAGR, COVID-19 impact.

The Data C...